Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nkarta, Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 3 distinct art units. SKOKO III, JOHN JOSEPH is the busiest examiner, with 1 pending matter, so the examiner assignments are separate while one art unit receives more than one pending matter.
Counsel should use centralized portfolio review for biotechnology and pharmaceutical terminology, specification support, and recurring technical issues. The examiner count indicates that each pending matter requires an individualized prosecution plan, while the art-unit overlap may support limited grouping for technical review. Any shared strategy should remain subordinate to the cited record and claim scope in each application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
| LIU, SUE XU | 1 | 20.9% | +18.6% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559514 | DOSING REGIMENS FOR CANCER IMMUNOTHERAPY | LIU, SUE XU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024012 | ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | VAN BUREN, LAUREN K | 17d overdue |
| 18657550 | GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY | SKOKO III, JOHN JOSEPH | — |
| 18578164 | BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODS | SHUPE, ELIZABETH A | — |
| 18559514 | DOSING REGIMENS FOR CANCER IMMUNOTHERAPY | LIU, SUE XU | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1616 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18657550 | GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY | SKOKO III, JOHN JOSEPH | 1643 | §112Other | Final Rejection | — | Pending | May 07, 2024 |
| 18578164 | BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODS | SHUPE, ELIZABETH A | 1643 | §112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18559514 | DOSING REGIMENS FOR CANCER IMMUNOTHERAPY | LIU, SUE XU | 1616 | §103Other | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18024012 | ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | VAN BUREN, LAUREN K | 1638 | §103 | Non-Final OA | 17d overdue | Pending | Feb 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNkarta, Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
John Joseph Skoko III has the most, with 1 of Nkarta, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
